124 Results

People

  1. Hassoun
    Hassoun
  2. Lesokhin
    Lesokhin
  3. Mailankody
    Mailankody
  4. Korde
    Korde
  5. Giralt
    Giralt
  6. Landau
    Landau
  7. Chung
    Chung
  8. Shah
    Shah
  9. Shah
    Shah
  10. Hultcrantz
    Hultcrantz

Groups

  1. Center for Hematologic Malignancies (124)
  2. Department of Medicine (124)
  3. Hematologic Malignancies Research (124)
  4. Hematologic Malignancies, Division of (124)
  5. Myeloma (124)
  6. Survivorship Research (124)
  7. Bone Marrow Transplant (107)
  8. Sloan Kettering Institute Postdocs (106)
  9. CTCR Scholars (100)
  10. Epidemiology and Biostatistics (87)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Hani Hassoun"
  4. "Sham Mailankody"
Formats
  1. Meeting Abstract (92)
  2. Journal Article (24)
  3. Research Letter (6)
  4. Correspondence (2)
Groups
  1. Center for Hematologic Malignancies (124)
  2. Department of Medicine (124)
  3. Hematologic Malignancies Research (124)
  4. Hematologic Malignancies, Division of (124)
  5. Myeloma (124)
  6. Survivorship Research (124)

More Groups

People
  1. Alexander Lesokhin (124)
  2. Hani Hassoun (124)
  3. Sham Mailankody (124)
  4. Neha Korde (121)
  5. Malin Hultcrantz (105)
  6. Sergio Giralt (103)

More People

Years
  1. 2024 (1)
  2. 2023 (33)
  3. 2022 (31)
  4. 2021 (13)
  5. 2020 (11)
  6. 2019 (12)

More Years

Publications
  1. Blood (50)
  2. Clinical Lymphoma, Myeloma and Leukemia (31)
  3. Leukemia and Lymphoma (8)
  4. Journal of Clinical Oncology (7)
  5. Biology of Blood and Marrow Transplantation (5)
  6. American Journal of Hematology (3)

More Publications

Publishers
  1. American Society of Hematology (51)
  2. Elsevier Inc. (39)
  3. Taylor & Francis Group (8)
  4. American Society of Clinical Oncology (7)
  5. American Association for Cancer Research (3)
  6. John Wiley & Sons, Inc. (3)

More Publishers

Results (124)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience
    Research Letter

    Mohan, M.; Becnel, M. R.; Shah, U. A.; Dong, H.; Gundarlapalli, S.; Peterson, T.; Orozco, J. S.; Horowitz, S.; Chhabra, S.; Dhakal, B.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Capture rate of V(D)J sequencing for minimal residual disease detection in multiple myeloma
    Journal Article

    Hultcrantz, M.; Rustad, E. H.; Yellapantula, V.; Jacob, A.; Akhlaghi, T.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Smith, E. L.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Nutrition perceptions, needs and practices among patients with plasma cell disorders
    Research Letter

    Malik, M. A.; Sweeney, N. W.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P. A.; Mailankody, S.; Korde, N.; Tan, C. R.; Hassoun, H.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Journal Article

    Piedra, K.; Peterson, T.; Tan, C.; Orozco, J.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U.; Lu, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
    Research Letter

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A pilot plant-based dietary intervention in overweight and obese patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma- the Nutrition Prevention (NUTRIVENTION) study
    Meeting Abstract

    Shah, U. A.; Alicea, D.; Adintori, P. A.; Burge, M.; Blaslov, J.; Derkach, A.; Mailankody, S.; Korde, N.; Tan, C.; Hultcrantz, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save